Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
South Korea’s Hanmi Pharm Co., Celltrion Inc., and Dongbang FTL were among 27 drugmakers chosen to produce low-cost versions of Merck & Co.’s COVID-19 pill molnupiravir for low- and-middle-income countries.
The Medicines Patent Pool (MPP), an UN-backed public health organization, announced that it signed sublicense agreements with 27 generic drug manufacturers to produce molnupiravir to be supplied to 105 countries.
Celltrion will manufacture the finished drug and Dongbang FTL will produce ingredients, while Hanmi will do both.
The MPP signed a licensing agreement with the US drugmaker last year to boost global access for molnupiravir.
The South Korean government would support its three pharmaceutical companies involved in the deal by easing regulations and establishing a consultative entity involving government ministries and companies.
According to MPP, which works to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries, the companies offered the sublicense have demonstrated their ability to meet its requirements for production capacity, regulatory compliance, and the ability to meet international standards for quality-assured medicines.
The MPP’s list of 27 generic manufacturers also includes 10 Indian and two Chinese firms.
Out of the 27 companies, 13 will produce both raw ingredients and the finished drug, according to the MPP.
